A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.

Abstract (PubMed)

Convalescent plasma is frequently administered to patients with Covid-19. We randomly assigned hospitalized adult patients with severe Covid-19 pneumonia in a 2:1 ratio to receive convalescent plasma or placebo. The primary outcome was the patient's clinical status 30 days after the intervention, measured on a six-point ordinal scale (total recovery to death). 228 patients received convalescent plasma and 105 placebo. Median time from symptom onset to enrollment: 8 days (IQR 5–10). Infused plasma had median titer 1:3200 of total SARS-CoV-2 antibodies. Odds ratio for clinical status at day 30: 0.83 (95% CI 0.52–1.35; P=0.46). Mortality: 10.96% plasma vs 11.43% placebo. No significant difference observed. Adverse events were similar in both groups.